Deregulated Polycomb functions in myeloproliferative neoplasms

Area of Science:

• Epigenetics and Gene Regulation
• Cancer Biology
• Hematology

Background:

• Polycomb Repressive Complexes (PRCs) are key epigenetic regulators maintaining gene silencing through histone modifications and chromatin compaction.
• The balance between PRC complexes and Trithorax-group complexes fine-tunes gene expression essential for development and tissue homeostasis.
• Dysregulation of PRCs, through altered expression or mutations, is implicated in various cancers, including hematological malignancies.

Purpose of the Study:

• To review recent findings on the role of Polycomb Repressive Complexes (PRCs) in the pathogenesis of myeloproliferative neoplasms (MPNs).
• To discuss the therapeutic potential of targeting the pathological functions of PRCs in MPN treatment.

Main Methods:

• Review of genetic and biochemical studies on Polycomb proteins and their complexes.
• Analysis of research on the involvement of PRC2 (EZH2, ASXL1) and non-canonical PRC1 (BCOR) in hematological malignancies.
• Synthesis of recent findings concerning PRC roles in MPN pathogenesis and therapeutic strategies.

Main Results:

• PRC complexes, including PRC2 and PRC1 components like EZH2, ASXL1, and BCOR, play significant roles in the pathogenesis of hematological malignancies such as MPNs.
• The tumor-suppressive functions of EZH2-containing PRC2 and ASXL1, as well as BCOR, are critical in preventing MPN development.
• Altered expression or mutations in PRC genes contribute to the dysregulation observed in cancer cells.

Conclusions:

• Polycomb Repressive Complexes are critical players in the development and progression of myeloproliferative neoplasms.
• Targeting the aberrant functions of PRCs presents a promising therapeutic avenue for treating MPNs.